Skip to content
Boca Raton City Online – Lifestyle
Author:
GENFIT S.A.
GENFIT: NASHnext®, Powered by GENFIT’s Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
June 8, 2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
May 25, 2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
May 21, 2026
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
April 20, 2026
GENFIT Announces Publication of the 2025 Universal Registration Document
April 7, 2026
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
April 2, 2026
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
March 10, 2026
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
March 6, 2026